Hemophilia A and B are rare X-linked bleeding disorders caused by mutations in the genes
encoding coagulation factor VIII (FVIII) and factor IX (FIX). Hemophilia A (HA) is more …

Virchow's triad is traditionally invoked to explain pathophysiologic mechanisms leading to
thrombosis, alleging concerted roles for abnormalities in blood composition, vessel wall …

Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence‐
based guidelines offer practical recommendations on the diagnosis and general …

Background Effective ways to prevent arthropathy in severe hemophilia are unknown.
Methods We randomly assigned young boys with severe hemophilia A to regular infusions …

Background: Prophylactic treatment for severe hemophilia A is likely to be more effective
than treatment when bleeding occurs, however, prophylaxis is costly. We studied an …

In patients with haemophilia, regular replacement therapy with clotting factor concentrates
(prophylaxis) is effective in preventing recurrent bleeding episodes into joints and muscles …

Development of inhibitors against factor VIII (FVIII) or factor IX (FIX) in haemophilia patients
is one of the most serious complications of repeated exposure to replacement therapy and …

In persons with hemophilia, life expectancy is now approaching that of the general male
population, at least in countries that can afford regular replacement therapy with coagulation …

The most significant complication of treatment in patients with hemophilia A is the
development of alloantibodies that inhibit factor VIII activity. In the presence of inhibitory …

Lack of detailed natural history and outcomes data for neonates and toddlers with
haemophilia hampers the provision of optimal management of the disorder. We report an …